EUCTR2005-006157-24-DE进行中（未招募）不适用
A multicenter open label phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma - APO866 for CTC
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible for inclusion into this study, the patients must fulfil all of the following criteria:
- •Histologically confirmed diagnosis of CTCL including mycosis fungoides and Sézary syndrome or others according the WHO/EORTC classification18
- •Stage Ib to IVb disease (AJCC TNM staging)
- •Relapsed or refractory disease or intolerant to = 2 prior systemic therapy. PUVA, topical nitrogen mustard, spot or total skin electron beam therapy or other radiotherapy, oral retinoids, immunotherapy (e.g. interferon-a, denileukin difitox, alemtuzumab) or mono- or poly-chemotherapy regimen will be considered systemic therapy.
- •ECOG performance status < 2
- •Age > 18 years, of either sex.
- •Have given written informed consent, prior to any study related procedure not part of the patient’s normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •To be eligible for inclusion in this study the patients must not meet any of the following criteria:
- •Have participated in any other investigational study or received an experimental therapeutic procedure considered to interfere with the study in the 2 months preceding SD1
- •Have had PUVA, topical nitrogen mustard, spot or total skin electron beam therapy, oral retinoids, or any, immunotherapy (e.g. interferon-a, denileukin difitox, alemtuzumab) or chemotherapy regimen within 2 weeks of SD1. Patients must have recovered of all acute toxicities.
- •Evidence of CNS lymphoma
- •Use of concomitant prohibited medication due to CYP3A4 metabolism of APO866
- •Use of bisphosphonate drugs during the 30 days preceding the APO866 perfusion
- •Uncontrolled medical conditions, requiring surgical or pharmacological treatment (exceptions must be approved by the Study Director).
- •Serious concomitant disease (e.g. significant cardiac disease) are not eligible
- •Primary or acquired thrombocytopenia
- •Inadequate bone marrow reserve: WBC < 3.5x109/L, neutrophils < 1.0x109/L, thrombocytes < 100x109/L, Hb < 8.5 g/dL or coagulation abnormalities
- •Inadequate liver function: total bilirubin > 1.5 x upper limit of normal values (ULN), AST, ALT, or alkaline phosphatase > 2.5 x ULN
- •Have inadequate renal function, defined by serum creatinine > 250 mmol/L
- •Retinopathy, history of retinal laser surgery, or in the case of abnormal result on either of the corrected visual acuity color vision, threshold visual field, Amsler grid and fundus oculi tests, an ERG < 50% of normal
- •Pregnant or breastfeeding. Female patients with child-bearing potential must be using a hormonal contraceptive, intra-uterine device, diaphragm with spermicide or condom with spermicide for the duration of the study. Women of childbearing potential must have a negative serum or urinary hCG pregnancy test. Females whom are surgically sterile or post-menopausal are eligible for the study.
研究者
相似试验
进行中（未招募）
不适用
An multicenter open label phase II study to assess the efficiency and safety of APO866 in the treatment patients with refractory or relapsed cutaneous T-cell lymphoma - APO866 for CTCPrimary cutaneous lymphomas are non-Hodgkin lymphomas that present to the skin without evidence of extracutaneous disease at the time of diagnosis. It refers to either to cutaneous T-cell lymphoma (CTCL) or cutaneous B-cell lymphoma (CBCL). The primary cutaneous lymphomas are classified according to the WHO-EORTC classification. CTCL constitutes about 65% of all primary cutaneous lymphomas, of which mycosis fungoides is the most prevalent clinical presentation.MedDRA version: 8.1Level: PTClassification code 10028483EUCTR2005-006157-24-ATTopoTarget A/S25
进行中（未招募）
不适用
A multicenter open label phase II study to evaluate the safety and efficacy of deferasirox in combination with deferioxamine followed by transitioning to deferasirox monotherapy in ß-thalassemia patients with severe cardiac iron overload - DFX AutonomyEUCTR2009-018091-34-GRovartis (Hellas) S.A.C.I52
进行中（未招募）
1 期
A multicenter phase II open label study to evaluate efficacy of concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanomaEUCTR2016-002114-50-SESahlgrenska University Hospital29
进行中（未招募）
1 期
Study of safety, pharmacokinetics, and anti-tumor activity of GTAEXS617 in patients with advanced solid tumors.advanced solid tumorsMedDRA version: 21.0Level: PTClassification code 10052360Term: Colorectal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10051971Term: Pancreatic adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10006204Term: Breast carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061328Term: Ovarian epithelial cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-003475-42-BEExscientia AI Ltd177
进行中（未招募）
1 期
edosiran in Pediatric Patients from Birth to 5 Years of Age with PH1, PH2, or PH3 and Relatively Intact Renal FunctioPrimary HyperoxaluriaMedDRA version: 20.1Level: PTClassification code 10020703Term: HyperoxaluriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2021-001083-16-ESDicerna Pharmaceuticals Inc15